Genentech, United States, is a wholly owned member of the Roche Group.
美国的基因技术公司是罗氏集团的拥有成员。
Microsoft, Genentech, Gap and The Limited were all founded during recessions.
公司 ，盖普有限公司都是在经济衰退时期建立的。
Roche, another Swiss drug giant, bought Genentech and its busy cancer pipeline in 2009.
2009年瑞士罗氏制药公司收购了“基因技术公司”及其忙碌的生产线。
Genentech also subsidizes the cost of accessing two onsite childcare centers at its headquarters.
基因泰克的总部设有两个日托中心，员工可以获得入托费用补贴。
So Genentech developed a monoclonal antibody, a type of protein, that would bind to VEGF and disable it.
因此基因泰克公司开发了一种单克隆抗体，这种蛋白将绑定VEGF而使之失效。
The bosses of both Genentech and ImClone have unceremoniously rejected the offers made by their partners.
基因技术公司和从英克隆公司的老板都随随便便地就拒绝了收购的出价。
The ten stocks were Nokia, Nortel, Enron, Oracle, Broadcom, Viacom, Univision, Schwab, Morgan Stanley, and Genentech.
这十只股票分别是：诺基亚、北电、安然公司、甲骨文、博通、维亚康姆、联视、嘉信理财、摩根·士丹利和遗传技术研究公司。
In June, Abbott Laboratories Inc. and Genentech said they would collaborate to develop a cancer drug using this approach.
六月份，雅培公司和基因泰克公司宣布，两公司将运用这种方法合作开发一种抗癌药。
But an unusual conflict of interest means that Genentech, the drug company that produces Lucentis, is conspicuously silent.
但是一个不同寻常的利益冲突意味着制药公司基因泰克对此格外地沉默。
"There is no interference in the way we do things, " insists Richard Scheller, head of research and early development at Genentech.
曾经供职于基因泰克开发部、现任罗氏研发负责人的理查德•塞勒强调，“没人会干涉我们行事的方式。”
Eric Schmidt, Google's chief executive, and Arthur Levinson, a former boss of Genentech, a biotech company, sit on the boards of both firms.
埃里克斯密特和阿瑟莱文森都同时为两家公司董事会成员。 前者是苹果公司首席执行官，后者是一家生物科技公司-基因技术公司的前任老板。
But a number of drug companies including Genentech and Novartis AG are looking at small molecule cancer drugs that can get inside cells and block VEGF.
包括基因泰克和诺华制药在内的一些制药公司正在研究可以进入细胞内部并阻断VEGF的小分子抗癌药物。
By taking over Genentech, Roche has added promising drugs for cancer and other potentially lucrative treatments to its otherwise anaemic research pipeline.
通过收购基因泰克，罗氏已经在其贫血症研究方面，增加了抗癌药和其他潜在有利可图的、有前景的治疗方法。
Mr Stefansson is crafting a new strategy for a “smaller, leaner” DeCode that, if properly financed, could one day grow into a biotech giant like Genentech.
Stefansson先生正在为更精干的公司制定新的战略。DeCode公司如果获得适当的财政援助，可能在将来的某一天成长为像Genentech公司那样的生物技术巨头。
Other drug firms using this critical technology now have to license it from Genentech until 2018, and the company could also simply refuse a license to a competitor.
如今，其他用到此项关键技术的公司，直到2018年都要向基因科技请求授权，但基因科技亦可直截了当地拒绝授权给竞争者。
For example, at Genentech, enormous banners featuring the patients who have a better quality of life—thanks to the drugs Genentech produces—grace the sides of buildings.
举个例子，美国生物技术巨头基因泰克在办公室墙上挂了一些巨型横幅，内容都是病人感谢基因泰克制造的药品提高了生活品质。
D. A. approval for that purpose would enable Genentech to advertise and promote the drug as a breast cancer treatment and probably make insurers more willing to pay for it.
但食物与药品管理局批准该药将利于Genentech通过广告宣传并促进该药成为乳腺癌的治疗用药，这样更有可能使保险公司为它投保。
Genentech is seeking approval of Avastin as a combination treatment with the chemotherapy drug paclitaxel in women with advanced breast cancer who haven't had chemo before.
基因泰克是寻求批准阿伐斯汀在患者没有接受化疗之前，作为一个与化疗药物紫杉醇联用来治疗晚期乳腺癌妇女。
Axitinib was designed to block the creation of blood vessels that feed tumors, similar to Genentech Inc. 's (DNA) Avastin, which is used to treat colorectal and lung cancers.
阿西替尼通过抑制肿瘤血管的生成来起到抗癌的作用，与基因技术公司开发的阿瓦斯丁（该药物用于治疗结肠癌和肺癌）类似。
In the second study, Dr. Ingrid Wertz of Genentech in San Francisco and her colleagues focused on certain widely prescribed anti-cancer drugs, including Taxol and vincristine.
在第二项试验中，来自旧金山Genentech公司的IngridWertz博士和他的同事研究的是包括紫杉醇和长春新碱在内的一大类处方类抗癌药物。
A breakthrough came more than a decade ago when Genentech, a Californian biotech firm, launched a drug that attacks breast-cancer cells with too much of a certain protein, HER2.
十多年前就取得了重大进展，一个加州的生物科技公司Genentech(中文名：基因泰克)发行了一种药物，这种药物攻击蛋白质HER2(中文名：人表皮生长因子受体- 2)含量过多的乳腺癌细胞。
Yet while Google has been able to sign up some large clients such as Genentech and Motorola, it still gets the lion's share of its business from small and medium-sized companies.
谷歌虽然能够签下基因技术和摩托罗拉这样的一些大型用户，但在办公业务领域内大部分客户仍是中小型公司。
Soon afterwards Switzerland’s Roche decided to abandon its previously friendly overtures toward Genentech, a Californian biotechnology pioneer, in favour of a hostile takeover bid.
紧接着，瑞典罗氏药厂决定放弃此前对加利福利亚生物制药业领头羊基因泰科公司提出的温和收购方案，转之对其进行恶意收购。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
应用推荐